To test this hypothesis, we first evaluated the effects of docetaxel, a commonly used chemotherapeutic agent for PCa,49 and PDPK1 inhibitors (GSK2334470 and BX795) on a panel of PCa cells (DU145, PC3 and LNCaP). Here, PDPK1 is linked to posterior cortical atrophy.